{
    "organizations": [],
    "uuid": "95bbef0606b08c7976f313762d17997ea2eac5cb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mimedx-reports-positive-results-fr/brief-mimedx-reports-positive-results-from-phase-2b-clinical-trial-of-amniofix-injectable-idUSASC09TMW",
    "ord_in_thread": 0,
    "title": "BRIEF-Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Mimedx Group Inc:\n* MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS\n* MIMEDX GROUP INC - AMNIOFIX INJECTABLE ACHIEVES PRIMARY AND SECONDARY EFFICACY ENDPOINTS\n* MIMEDX GROUP INC - ‍STATISTICALLY SIGNIFICANT DIFFERENCE IN PAIN AND FUNCTION COMPARED TO PLACEBO​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-26T22:26:00.000+03:00",
    "crawled": "2018-03-27T11:44:27.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "mimedx",
        "group",
        "inc",
        "mimedx",
        "report",
        "positive",
        "pain",
        "foot",
        "function",
        "result",
        "phase",
        "2b",
        "clinical",
        "trial",
        "injectable",
        "treatment",
        "plantar",
        "fasciitis",
        "mimedx",
        "group",
        "inc",
        "amniofix",
        "injectable",
        "achieves",
        "primary",
        "secondary",
        "efficacy",
        "endpoint",
        "mimedx",
        "group",
        "inc",
        "significant",
        "difference",
        "pain",
        "function",
        "compared",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}